Pharming N.V.(PHAR) - 2022 Q4 - Earnings Call Presentation
Pharming N.V.(PHAR)2023-03-16 12:53www.pharming.com | investor@pharming.com Pharming Group N.V. Full Year 2022 Financial Results March 16, 2023 mm 2 �Pharming® MTT I Introduction One commercialized asset: RUCONEST® (rhC1INH) for the treatment of acute hereditary angioedema (HAE) | --- | --- | |-------|-----------------------------------------------------------------------------------------------------------| | | | | | Development of rare disease pipeline and leniolisib/ PI3Kδ for additional rare disease indications | EURONEXT Amsterdam: PHAR ...